Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] closed the trading session at $0.2 on 2025-10-17. The day’s price range saw the stock hit a low of $0.175, while the highest price level was $0.2183.
The stocks have a year to date performance of -77.26 percent and weekly performance of 8.22 percent. The stock has been moved at -15.99 percent over the last six months. The stock has performed 25.06 percent around the most recent 30 days and changed -27.63 percent over the most recent 3-months.
If compared to the average trading volume of 96.21M shares, ADAP reached to a volume of 38932271 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Adaptimmune Therapeutics Plc ADR [ADAP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADAP shares is $0.28 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADAP stock is a recommendation set at 3.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Adaptimmune Therapeutics Plc ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 29, 2025. The new note on the price target was released on June 26, 2025, representing the official price target for Adaptimmune Therapeutics Plc ADR stock. Previously, the target price had yet another raise to $4, while H.C. Wainwright analysts kept a Buy rating on ADAP stock.
ADAP stock trade performance evaluation
Adaptimmune Therapeutics Plc ADR [ADAP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.22. With this latest performance, ADAP shares gained by 25.06% in over the last four-week period, additionally sinking by -15.99% over the last 6 months – not to mention a drop of -62.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADAP stock in for the last two-week period is set at 61.66, with the RSI for the last a single of trading hit 0.0397, and the three-weeks RSI is set at 0.0329 for Adaptimmune Therapeutics Plc ADR [ADAP]. The present Moving Average for the last 50 days of trading for this stock 0.1051, while it was recorded at 0.1839 for the last single week of trading, and 0.2958 for the last 200 days.
Adaptimmune Therapeutics Plc ADR [ADAP]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Adaptimmune Therapeutics Plc ADR [ADAP] shares currently have an operating margin of -236.46% and a Gross Margin at 78.45%. Adaptimmune Therapeutics Plc ADR’s Net Margin is presently recorded at -258.57%.
Adaptimmune Therapeutics Plc ADR (ADAP) Capital Structure & Debt Analysis
Adaptimmune Therapeutics Plc ADR (ADAP) Efficiency & Liquidity Metrics
Adaptimmune Therapeutics Plc ADR (ADAP) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Adaptimmune Therapeutics Plc ADR. (ADAP) effectively leverages its workforce, generating an average of -$335553.36 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.52% and a Quick Ratio of 1.29%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Adaptimmune Therapeutics Plc ADR [ADAP] stock
With the latest financial reports released by the company, Adaptimmune Therapeutics Plc ADR posted -0.01/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.17. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADAP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptimmune Therapeutics Plc ADR go to -11.87%.
Adaptimmune Therapeutics Plc ADR [ADAP]: Institutional Ownership
There are presently around $31.28%, or 31.48%% of ADAP stock, in the hands of institutional investors. The top three institutional holders of ADAP stocks are: MATRIX CAPITAL MANAGEMENT COMPANY, LP with ownership of 38.97 million shares, which is approximately 2.5415%. ECOR1 CAPITAL, LLC, holding 27.4 million shares of the stock with an approximate value of $$26.72 million in ADAP stocks shares; and ECOR1 CAPITAL, LLC, currently with $$16.65 million in ADAP stock with ownership which is approximately 1.1138%.
